

Carla Casulo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9574472/publications.pdf>

Version: 2024-02-01

50
papers

1,586
citations

759233

12
h-index

315739

38
g-index

50
all docs

50
docs citations

50
times ranked

2272
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2516-2522.	1.6	610
2	Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 91-103.	10.7	236
3	Transformed follicular non-Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 40-47.	1.4	132
4	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
5	Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted <sc>EPOCH</sc>. <i>British Journal of Haematology</i> , 2017, 179, 739-747.	2.5	101
6	Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials. <i>Blood</i> , 2022, 139, 1684-1693.	1.4	56
7	Dual targeting of the thioredoxin and glutathione antioxidant systems in malignant B cells: A novel synergistic therapeutic approach. <i>Experimental Hematology</i> , 2015, 43, 89-99.	0.4	44
8	Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. <i>Oncotarget</i> , 2015, 6, 14796-14813.	1.8	42
9	Burkitt lymphoma- a rare but challenging lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 279-284.	1.7	37
10	How I treat early-relapsing follicular lymphoma. <i>Blood</i> , 2019, 133, 1540-1547.	1.4	33
11	Safety and Preliminary Efficacy Results of a Phase I First-in-Human Study of the Novel Notch-1 Targeting Antibody Brontictuzumab (OMP-52M51) Administered Intravenously to Patients with Hematologic Malignancies. <i>Blood</i> , 2016, 128, 5108-5108.	1.4	23
12	Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 372-378.	0.8	15
13	Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial: Dose Optimization Efficacy Update and Expansion Phase Initial Results. <i>Blood</i> , 2020, 136, 38-39.	1.4	14
14	Contempo: Preliminary Results in First-Line Treatment of Follicular Lymphoma with the Oral Dual PI3K- γ Inhibitor, Duvelisib, in Combination with Rituximab or Obinutuzumab. <i>Blood</i> , 2016, 128, 2979-2979.	1.4	12
15	Results of a Phase Ib Study of Venetoclax Plus R- or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 3032-3032.	1.4	12
16	How I manage patients with follicular lymphoma. <i>British Journal of Haematology</i> , 2019, 186, 513-523.	2.5	9
17	Durvalumab (Anti PD-L1) As Monotherapy or in Combination Therapy for Relapsed/Refractory (r/r) Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL): A Subgroup Analysis from the Phase 1/2 Fusion NHL-001 Global Multicenter Trial. <i>Blood</i> , 2019, 134, 5320-5320.	1.4	9
18	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019, 134, 69-69.	1.4	9

#	ARTICLE	IF	CITATIONS
19	Metabolic Abnormalities Detected in Phase II Evaluation of Doxycycline in Dogs with Multicentric B-Cell Lymphoma. <i>Frontiers in Veterinary Science</i> , 2018, 5, 25.	2.2	8
20	Follicular Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 627-638.	2.2	7
21	Early Relapse in First-Line Follicular Lymphoma: A Review of the Clinical Implications and Available Mitigation and Management Strategies. <i>Oncology and Therapy</i> , 2021, 9, 329-346.	2.6	7
22	Prognostic factors in follicular lymphoma: new tools to personalize risk. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 269-276.	2.5	6
23	Safety and Toxicity Profile of Pembrolizumab (PEM) in Combination with ICE Chemotherapy Followed By Autologous Stem Cell Transplantation for Relapsed/Refractory Classical Hodgkin Lymphoma: No Impairment in Stem Cell Mobilization or Engraftment. <i>Blood</i> , 2019, 134, 4029-4029.	1.4	6
24	Patient Characteristics and Initial Treatment Patterns in the United States for the Most Common Subtypes of Peripheral T-Cell Lymphoma (PTCL). <i>Blood</i> , 2014, 124, 4434-4434.	1.4	6
25	Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The <sc>FUSION NHL</sc> 001 trial. <i>Cancer Reports</i> , 2023, 6, .	1.4	6
26	Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 322-328.e2.	0.4	5
27	Body mass index and survival of patients with lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 2671-2678.	1.3	5
28	Benefit from the inclusion of radiation therapy in the treatment of patients with stage III classical Hodgkin lymphoma: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database. <i>Radiotherapy and Oncology</i> , 2017, 124, 325-330.	0.6	4
29	Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation. <i>Leukemia and Lymphoma</i> , 2019, 60, 3569-3572.	1.3	4
30	A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 5-6.	1.4	4
31	Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database. <i>Blood</i> , 2019, 134, 1610-1610.	1.4	3
32	Correlates of anxiety and depression in chronic lymphocytic leukemia (CLL) survivors.. <i>Journal of Clinical Oncology</i> , 2018, 36, 153-153.	1.6	3
33	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.	5.2	3
34	Early Progressing Follicular Lymphoma. <i>Current Oncology Reports</i> , 2021, 23, 149.	4.0	2
35	Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 598-605.	1.3	1
36	A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 2834-2834.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Risk Factors and Outcomes of Patients with Follicular Lymphoma Who Had Histologic Transformation at First Progression after First-Line Immunochemotherapy in the Gallium Study. Blood, 2019, 134, 5268-5268.	1.4	1
38	A Novel Method for Identifying Transgender and Gender Diverse Patients with Lymphoma: A Single Center Experience. Blood, 2019, 134, 5825-5825.	1.4	1
39	Disease Characteristics, Treatment Patterns, and Outcomes of Follicular Lymphoma in Patients 40 Years of Age and Younger: An Analysis from the National LymphoCare Study. Blood, 2014, 124, 3044-3044.	1.4	1
40	Ofatumumab-Bendamustine As First Line Treatment for Elderly Patients with Mantle Cell Lymphoma: A Phase II Risk Adapted Design with Comprehensive Geriatric Assessment. Blood, 2014, 124, 1751-1751.	1.4	1
41	Central line-associated complications during treatment with DA-R-EPOCH therapy for NHL.. Journal of Clinical Oncology, 2017, 35, 7543-7543.	1.6	1
42	Arrhythmia Burden in Patients with Indolent Lymphoma. Blood, 2020, 136, 6-7.	1.4	1
43	Late Relapses Following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era. Blood, 2014, 124, 3999-3999.	1.4	0
44	Consolidative Radioimmunotherapy after Chemoimmunotherapy in Patients with Histologic Transformation of Indolent Lymphoma. Blood, 2014, 124, 1746-1746.	1.4	0
45	Phase I/II study of durvalumab (anti-PD-L1 antibody) as monotherapy and in combination in patients with lymphoma or chronic lymphocytic leukemia.. Journal of Clinical Oncology, 2017, 35, TPS7574-TPS7574.	1.6	0
46	Enrollment of high-risk patients with diffuse large B-cell lymphoma in clinical trials.. Journal of Clinical Oncology, 2017, 35, 6536-6536.	1.6	0
47	Using Real World Data (RWD) to Identify Care Needs in an Adolescent and Young Adult (AYA) Lymphoma Population: A Match Cohort Study. Blood, 2021, 138, 3053-3053.	1.4	0
48	Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Blood, 2021, 138, 2640-2640.	1.4	0
49	Regional Differences in Lymphomagenesis Identified through Quantification of AICDA-Mediated Subclonal Evolution in Follicular Lymphoma: Do Pesticides Play a Role?. Blood, 2021, 138, 3505-3505.	1.4	0
50	Hypergammaglobulinemia as a presenting feature of Mantle cell lymphoma. Leukemia and Lymphoma, 2022, , 1-4.	1.3	0